文献速递炎症性肠病

系统综述与Meta分析:炎症性肠病中乌司奴单抗失应答及剂量递增需求

Systematic review with meta-analysis: loss of response and requirement of ustekinumab dose escalation in inflammatory bowel diseases.
PubMed 文献 · Aliment Pharmacol Ther · 2022-02-09

该系统综述与Meta分析检索截至2021年7月的数据库,纳入14项研究(克罗恩病13项、溃疡性结肠炎1项)。克罗恩病原发应答者乌司奴单抗年失应答风险为21%/人年,剂量递增需求风险为25%/人年;剂量递增后58%的继发无应答者重获临床应答。溃疡性结肠炎失应答数据不足。

要点

  • 克罗恩病原发应答者乌司奴单抗年失应答风险21%/人年,年剂量递增需求风险25%/人年。
  • 克罗恩病继发无应答者剂量递增后58%重获临床应答。
  • 溃疡性结肠炎失应答数据有限,仅1项研究报告剂量递增年风险18%/人年。

核心结论

  • 克罗恩病原发应答者乌司奴单抗失应答风险为21%/人年,剂量递增需求风险为25%/人年。
  • 58%的克罗恩病继发无应答者可能从剂量递增中获益。
  • 溃疡性结肠炎患者的失应答尚未得到充分描述。

研究设计与样本

  • 系统综述与Meta分析,检索数据库自建库至2021年7月的合格研究,合并汇总估计值并进行亚组分析以探索异质性。
  • 共纳入14项研究,其中克罗恩病13项、溃疡性结肠炎1项。

主要发现

  • 克罗恩病原发应答者乌司奴单抗年失应答风险为21%(95%CI 12-31%,1530人年,n=9)。
  • 克罗恩病原发应答者年剂量递增需求风险为25%(95%CI 12-32%,657人年,n=5)。
  • 克罗恩病继发无应答者剂量递增(缩短间隔或静脉再诱导)后58%(95%CI 49-67%,279例,n=8)重获临床应答。
  • 溃疡性结肠炎无研究提供失应答数据;仅1项研究显示35%(100/284)患者接受剂量递增(或假性剂量调整),年剂量递增风险为18%/人年。
  • 溃疡性结肠炎剂量递增后58%(14/24)患者重获症状缓解。

关键数值与推荐

  • 克罗恩病原发应答者年失应答风险21%/人年(95%CI 12-31%,1530人年,n=9)。
  • 克罗恩病原发应答者年剂量递增需求风险25%/人年(95%CI 12-32%,657人年,n=5)。
  • 克罗恩病继发无应答者剂量递增后重获临床应答比例58%(95%CI 49-67%,279例,n=8)。
  • 溃疡性结肠炎剂量递增年风险18%/人年,基于35%(100/284)接受剂量递增或假性剂量调整的患者。
  • 溃疡性结肠炎剂量递增后重获症状缓解比例58%(14/24)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 溃疡性结肠炎患者中失应答尚未得到充分描述。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ustekinumab is effective in treating Crohn's disease (CD) and ulcerative colitis (UC). However, the loss of response (LOR) to ustekinumab and the efficacy of dose escalation have not been systematically explored. METHODS: Databases were searched for eligible studies from inception through July 2021. Summary estimates were pooled, and subgroup analyses were performed to explore heterogeneity. RESULTS: We included 14 studies (CD: 13; UC: 1). In CD patients, the annual risk of LOR to ustekinumab and dose escalation among primary responders was 21% (95% confidence interval [CI] 12-31%, 1530 person-years, n = 9) per person-year and 25% (95% CI 12-32%, 657 person-years, n = 5) per person-year respectively. Clinical response was regained in 58% (95% CI 49-67%, 279 patients, n = 8) of secondary non-responders after dose escalation (interval reduction or intravenous reinduction). In UC patients, no studies provided data on LOR, but only one study showed that 35% (100/284) of patients underwent dose escalation (or sham dose adjustment), leading to an annual risk of dose escalation of 18% per person-year. After dose escalation, 58% (14/24) of the patients regained symptomatic remission. CONCLUSIONS: Primary responders with CD experienced LOR to ustekinumab at a risk of 21% per person-year and required dose escalation at a risk of 25% per person-year. Fifty-eight per cent of secondary non-responders with CD may benefit from dose escalation. LOR has not been well characterized in patients with UC.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Yang H, Li B, Guo Q, et al. Systematic review with meta-analysis: loss of response and requirement of ustekinumab dose escalation in inflammatory bowel diseases. Aliment Pharmacol Ther. 2022. PMID: 35141914. doi:10.1111/apt.16802

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。